CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.
Praxis Precision Medicines Studying PRAX-114 in Essential Tremor and PRAX-944
Posted on June 7, 2021
Categories: In the News